Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates
Open Access
- 1 November 2014
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (11), 6454-6461
- https://doi.org/10.1128/aac.03620-14
Abstract
National treatment guidelines for invasive methicillin-resistant Staphylococcus aureus (MRSA) infections recommend targeting a vancomycin 24-h area under the concentration-time curve (AUC 0–24 )-to-MIC ratio of >400. The range of vancomycin trough concentrations that best predicts an AUC 0–24 of >400 in neonates is not known. This understanding would help clarify target trough concentrations in neonates when treating MRSA. A retrospective chart review from a level III neonatal intensive care unit was performed to identify neonates treated with vancomycin over a 5-year period. Vancomycin concentrations and clinical covariates were utilized to develop a one-compartment population pharmacokinetic model and examine the relationships between trough and AUC 0–24 in the study neonates. Monte Carlo simulations were performed to examine the effect of dose, postmenstrual age (PMA), and serum creatinine level on trough and AUC 0–24 achievement. A total of 1,702 vancomycin concentrations from 249 neonates were available for analysis. The median (interquartile range) PMA was 39 weeks (32 to 42 weeks) and weight was 2.9 kg (1.6 to 3.7 kg). Vancomycin clearance was predicted by weight, PMA, and serum creatinine level. At a trough of 10 mg/liter, 89% of the study neonates had an AUC 0–24 of >400. Monte Carlo simulations demonstrated that troughs ranging from 7 to 11 mg/liter were highly predictive of an AUC 0–24 of >400 across a range of PMA, serum creatinine levels, and vancomycin doses. However, a trough of ≥10 mg/liter was not readily achieved in most simulated subgroups using routine starting doses. Higher starting doses frequently resulted in troughs of >20 mg/liter. A vancomycin trough of ∼10 mg/liter is likely adequate for most neonates with invasive MRSA infections based on considerations of the AUC 0–24 . Due to pharmacokinetic and clinical heterogeneity in neonates, consistently achieving this target vancomycin exposure with routine starting doses is difficult. More robust clinical dosing support tools are needed to help clinicians with dose individualization.Keywords
This publication has 34 references indexed in Scilit:
- Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal InfectionsThe Pediatric Infectious Disease Journal, 2013
- Improved Vancomycin Dosing in Children Using Area Under the Curve ExposureThe Pediatric Infectious Disease Journal, 2013
- Methicillin-Resistant and Susceptible Staphylococcus aureus Bacteremia and Meningitis in Preterm InfantsPediatrics, 2012
- Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: A Monte Carlo simulationClinical Therapeutics, 2010
- Evaluation of different tests based on observations for external model evaluation of population analysesJournal of Pharmacokinetics and Pharmacodynamics, 2009
- Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant Staphylococcus aureus Infections Is InadequateThe Pediatric Infectious Disease Journal, 2009
- Human renal function maturation: a quantitative description using weight and postmenstrual agePediatric Nephrology, 2009
- Using the LMS method to calculate z-scores for the Fenton preterm infant growth chartEuropean Journal of Clinical Nutrition, 2007
- Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearanceBritish Journal of Clinical Pharmacology, 2006
- Modelling of individual pharmacokinetics for computer-aided drug dosageComputers and Biomedical Research, 1972